Abstract
Background
This study evaluates cardiovascular risk factors associated with progression of coronary artery disease (CAD) in patients with silent ischemia following myocardial infarction.
Hypothesis
Coronary artery disease only progresses slowly with comprehensive risk factor intervention.
Methods
A total of 104 of 201 patients (51.7%) of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II) with baseline and follow‐up coronary angiography were included. All patients received comprehensive cardiovascular risk factor intervention according to study protocol. Logistic regression was used to evaluate associations between baseline cardiovascular risk factors and CAD progression.
Results
The mean duration of follow‐up was 10.3±2.4 years. At baseline, 77.9% of patients were smokers, 45.2% had hypertension, 73.1% had dyslipidemia, 7.7% had diabetes, and 48.1% had a family history of CAD. At last follow‐up, only 27 patients of the initial 81 smokers still smoked, only 2.1% of the patients had uncontrolled hypertension, 10.6% of the patients had uncontrolled dyslipidemia, and 2.1% of the patients had uncontrolled diabetes. Coronary artery disease progression was found in up to 81 (77.9%) patients. Baseline diabetes and younger age were associated with increased odds of CAD progression. The time interval between baseline and follow‐up angiography was also associated with CAD progression.
Conclusion
Coronary artery disease progression was highly prevalent in these patients despite comprehensive risk factor intervention. Further research is needed to optimize treatment of known risk factors and to identify other unknown and potentially modifiable risk factors. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (124.5 KB).
References
- 1. Conti CR. Silent cardiac ischemia. Curr Opin Cardiol 2002;17: 537–542. [DOI] [PubMed] [Google Scholar]
- 2. Conti CR. Why we should attempt to eliminate (silent and symptomatic) ischemia in patients with chronic stable angina. Clin Cardiol 1998; 21: II8–11. [PubMed] [Google Scholar]
- 3. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation 2003; 108: 1263–1277. [DOI] [PubMed] [Google Scholar]
- 4. Erne P, Schoenenberger AW, Zuber M, et al. Effects of anti‐ischemic drug therapy in silent myocardial ischemia type I—the Swiss Interventional Study on Silent Ischemia Type I (SWISSI I): a randomized, controlled pilot study. Eur Heart J 2007; 28: 2110–2117. [DOI] [PubMed] [Google Scholar]
- 5. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007; 297: 1985–1991. [DOI] [PubMed] [Google Scholar]
- 6. Schoenenberger AW, Kobza R, Jamshidi P, et al. Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). Am J Cardiol 2009; 104: 158–163. [DOI] [PubMed] [Google Scholar]
- 7. Schoenenberger AW, Jamshidi P, Zuber M, et al. Coronary artery disease is common in asymptomatic patients with signs of myocardial ischemia. Eur J Intern Med 2009; 20: 607–610. [DOI] [PubMed] [Google Scholar]
- 8. Thaulow E, Erikssen J, Sandvik L, et al. Initial clinical presentation of cardiac disease in asymptomatic men with silent myocardial ischemia and angiographically documented coronary artery disease (the Oslo Ischemia Study). Am J Cardiol 1993; 72: 629–633. [DOI] [PubMed] [Google Scholar]
- 9. Alderman EL, Corley SD, Fisher LD, et al. Five‐year angiographic follow‐up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol 1993; 22: 1141–1154. [DOI] [PubMed] [Google Scholar]
- 10. Kramer JR, Matsuda Y, Mulligan JC, et al. Progression of coronary atherosclerosis. Circulation 1981; 63: 519–526. [DOI] [PubMed] [Google Scholar]
- 11. Moise A, Théroux P, Taeymans Y, et al. Clinical and angiographic factors associated with progression of coronary artery disease. J Am Coll Cardiol 1984; 3: 659–667. [DOI] [PubMed] [Google Scholar]
- 12. Moise A, Théroux P, Taeymans Y, et al. Factors associated with progression of coronary artery disease in patients with normal or minimally narrowed coronary arteries. Am J Cardiol 1985; 56: 30–34. [DOI] [PubMed] [Google Scholar]
- 13. Palmeri ST, Akula DN, Agarwal S, et al. Late angiographic follow‐up in adults with initial angiographic normal or minimally narrowed coronary arteries. Am J Cardiol 2007; 99: 1374–1377. [DOI] [PubMed] [Google Scholar]
- 14. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST‐Segment Elevation Myocardial Infarction: Executive Summary and Recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000; 102: 1193–1209. [DOI] [PubMed] [Google Scholar]
- 15. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction). Circulation 1999; 100: 1016–1030. [DOI] [PubMed] [Google Scholar]
- 16. Daly CA, Hildebrandt P, Bertrand M, et al; EUROPA Investigators. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 2007; 93: 1406–1411. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Kronmal RA, McClelland RL, Detrano R, et al. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi‐Ethnic Study of Atherosclerosis (MESA). Circulation 2007; 115: 2722–2730. [DOI] [PubMed] [Google Scholar]
- 18. Saely CH, Drexel H, Sourij H, et al. Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: an angiographic study. Atherosclerosis 2008; 199: 317–322. [DOI] [PubMed] [Google Scholar]
- 19. Haskell WL, Alderman EL, Fair JM, et al Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89: 975–990. [DOI] [PubMed] [Google Scholar]
- 20. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998; 280: 2001–2007. [DOI] [PubMed] [Google Scholar]
- 21. Kotseva K, Stagmo M, De Bacquer D, et al; EUROASPIRE II Study Group. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008; 197: 710–717. [DOI] [PubMed] [Google Scholar]
- 22. Gitt AK, Juenger C, Jannowitz C, et al. Guideline‐oriented ambulatory lipid‐lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil 2009; 16: 438–444. [DOI] [PubMed] [Google Scholar]
- 23. Schoenenberger AW, Radovanovic D, Stauffer JC, et al; Acute Myocardial Infarction in Switzerland Plus Investigators. Age‐related differences in the use of guideline‐recommended medical and interventional therapies for acute coronary syndromes: a cohort study. J Am Geriatr Soc 2008; 56: 510–516. [DOI] [PubMed] [Google Scholar]
- 24. Schoenenberger AW, Erne P, Ammann S, et al. Prediction of hypertensive crisis based on average, variability and approximate entropy of 24‐h ambulatory blood pressure monitoring. J Hum Hypertens 2008; 22: 32–37. [DOI] [PubMed] [Google Scholar]
- 25. Oguri M, Kato K, Hibino T, et al. Genetic risk for restenosis after coronary stenting. Atherosclerosis 2007; 194: e172–178. [DOI] [PubMed] [Google Scholar]